Canadian Journal of Neurological Sciences最新文献_第4页

Hyponatremia in Guillain-Barre Syndrome: A Review of Its Pathophysiology and Management. 吉兰巴雷综合征中的低钠血症：病理生理学和处理方法综述。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-02-16 DOI: 10.1017/cjn.2024.27

Archana B Netto, Niveditha Chandrahasa, Sheril S Koshy, Arun B Taly

{"title":"Hyponatremia in Guillain-Barre Syndrome: A Review of Its Pathophysiology and Management.","authors":"Archana B Netto, Niveditha Chandrahasa, Sheril S Koshy, Arun B Taly","doi":"10.1017/cjn.2024.27","DOIUrl":"10.1017/cjn.2024.27","url":null,"abstract":"Guillain-Barre syndrome (GBS) is the commonest cause of acute polyradiculoneuropathy that requires hospitalization. Many of these patients experience systemic and disease-related complications during its course. Notable among them is hyponatremia. Though recognized for decades, the precise incidence, prevalence, and mechanism of hyponatremia in GBS are not well known. Hyponatremia in GBS patients is associated with more severe in-hospital disease course, prolonged hospitalization, higher mortality, increased costs, and a greater number of other complications in the hospital and worse functional status at 6 months and at 1 year. Though there are several reports of low sodium associated with GBS, many have not included the exact temporal relationship of sodium or its serial values during GBS thereby underestimating the exact incidence, prevalence, and magnitude of the problem. Early detection, close monitoring, and better understanding of the pathophysiology of hyponatremia have therapeutic implications. We review the complexities of the relationship between hyponatremia and GBS with regard to its pathophysiology and treatment.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"9-19"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the Current State of Epilepsy Care in the Province of Ontario. 评估安大略省癫痫护理现状。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-01 DOI: 10.1017/cjn.2024.30

Christine Van Winssen, Andrea V Andrade, Danielle M Andrade, Jorge G Burneo, Sandrine de Ribaupierre, Elizabeth Donner, Ayman Hassan, George Ibrahim, Kevin C Jones, Lysa Boissé Lomax, Katherine Muir, Maryam N Nouri, Nikki Porter, Rajesh Ramachandrannair, Paul Raymond, James Rutka, Michelle J Shapiro, David A Steven, Darryl Swain, Taufik Valiante, Sharon Whiting, Robyn Whitney, Ivanna Yau, Tadeu A Fantaneanu

引用次数: 0

Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights. 加拿大医生使用肉毒杆菌毒素-A（BoNT-A）治疗瘫痪的调查：真实世界的洞察力。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-04-01 DOI: 10.1017/cjn.2024.46

Galit Kleiner, Farooq Ismail, Omar Khan, Christopher Pilieci, Linda Truong, Chris Boulias

引用次数: 0

Translation of the Preference-Based Amyotrophic Lateral Sclerosis Scale into French. 将基于偏好的肌萎缩侧索硬化症量表翻译成法文。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-02-20 DOI: 10.1017/cjn.2024.18

Ava Mehdipour, Lizabeth Teshler, Vanina Dal Bello-Haas, Vanessa Bouchard, Ayse Kuspinar

引用次数: 0

An Anatomical Perspective to Botulinum Toxin Injection of Flexor Digitorum Profundus. 从解剖学角度看屈指深肌的肉毒杆菌毒素注射。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-11 DOI: 10.1017/cjn.2024.34

Emma Stefanie Campisi, Omar Khan, Anne Marie Reet Agur, Rajiv Reebye

引用次数: 0

Cough Headache Responsive to Occipital Nerve Blockade. 对枕神经阻断术有反应的咳嗽性头痛

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-11 DOI: 10.1017/cjn.2024.17

Aqeel Almutairi, Tommy Lik Hang Chan

引用次数: 0

Atypical Bilateral Idiopathic Inflammatory Cavernous Sinus Syndrome Responsive to Cyclophosphamide. 对环磷酰胺有反应的非典型双侧特发性炎性海绵窦综合征

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-06 DOI: 10.1017/cjn.2024.29

Nabeela Nathoo, Kevin D Chodnicki, Jamie J Van Gompel, Karl N Krecke, Aivi T Nguyen, Michel Toledano, Orhun H Kantarci

引用次数: 0

Poststroke Care Pathways and Spasticity Treatment: A Retrospective Study in Alberta. 中风后护理路径和痉挛治疗：艾伯塔省的一项回顾性研究。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-22 DOI: 10.1017/cjn.2024.42

Lalith Satkunam, Sean P Dukelow, Jaime Yu, Stephen McNeil, Huong Luu, Karen J B Martins, Khanh Vu, Phuong Uyen Nguyen, Lawrence Richer, Tyler Williamson, Scott W Klarenbach

{"title":"Poststroke Care Pathways and Spasticity Treatment: A Retrospective Study in Alberta.","authors":"Lalith Satkunam, Sean P Dukelow, Jaime Yu, Stephen McNeil, Huong Luu, Karen J B Martins, Khanh Vu, Phuong Uyen Nguyen, Lawrence Richer, Tyler Williamson, Scott W Klarenbach","doi":"10.1017/cjn.2024.42","DOIUrl":"10.1017/cjn.2024.42","url":null,"abstract":"Background: Limited evidence exists regarding care pathways for stroke survivors who do and do not receive poststroke spasticity (PSS) treatment.Methods: Administrative data was used to identify adults who experienced a stroke and sought acute care between 2012 and 2017 in Alberta, Canada. Pathways of stroke care within the health care system were determined among those who initiated PSS treatment (PSS treatment group: outpatient pharmacy dispensation of an anti-spastic medication, focal chemo-denervation injection, or a spasticity tertiary clinic visit) and those who did not (non-PSS treatment group). Time from the stroke event until spasticity treatment initiation, and setting where treatment was initiated were reported. Descriptive statistics were performed.Results: Health care settings within the pathways of stroke care that the PSS (n = 1,079) and non-PSS (n = 22,922) treatment groups encountered were the emergency department (86 and 84%), acute inpatient care (80 and 69%), inpatient rehabilitation (40 and 12%), and long-term care (19 and 13%), respectively. PSS treatment was initiated a median of 291 (interquartile range 625) days after the stroke event, and most often in the community when patients were residing at home (45%), followed by \"other\" settings (22%), inpatient rehabilitation (18%), long-term care (11%), and acute inpatient care (4%).Conclusions: To our knowledge, this is the first population based cohort study describing pathways of care among adults with stroke who subsequently did or did not initiate spasticity treatment. Areas for improvement in care may include strategies for earlier identification and treatment of PSS.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"75-84"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yoga as an Add-on Therapy in Parkinson's Disease: A Single Group Open-label Trial. 瑜伽作为帕金森病的附加疗法：单组开放标签试验

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-25 DOI: 10.1017/cjn.2024.43

Pooja Mailankody, Nitish Kamble, Amitabh Bhattacharya, G S Shubha Bhat, Thamodharan Arumugam, K Thennarasu, Rashmi Arasappa, Shivarama Varambally, Ravi Yadav, Pramod Kumar Pal

{"title":"Yoga as an Add-on Therapy in Parkinson's Disease: A Single Group Open-label Trial.","authors":"Pooja Mailankody, Nitish Kamble, Amitabh Bhattacharya, G S Shubha Bhat, Thamodharan Arumugam, K Thennarasu, Rashmi Arasappa, Shivarama Varambally, Ravi Yadav, Pramod Kumar Pal","doi":"10.1017/cjn.2024.43","DOIUrl":"10.1017/cjn.2024.43","url":null,"abstract":"Objective: We aimed to evaluate the effect of yoga on motor and non-motor symptoms and cortical excitability in patients with Parkinson's disease (PD).Methods: We prospectively evaluated 17 patients with PD at baseline, after one month of conventional care, and after one month of supervised yoga sessions. The motor and non-motor symptoms were evaluated using the Unified Parkinson's disease Rating Scale (motor part III), Hoehn and Yahr stage, Montreal Cognitive Assessment, Hamilton depression rating scale, Hamilton anxiety rating scale, non-motor symptoms questionnaire and World Health Organization quality of life questionnaire. Transcranial magnetic stimulation was used to record resting motor threshold, central motor conduction time, ipsilateral silent period (iSP), contralateral silent period (cSP), short interval intracortical inhibition (SICI), and intracortical facilitation.Results: The mean age of the patients was 55.5 ± 10.8 years, with a mean duration of illness of 4.0 ± 2.5 years. The postural stability of the patients significantly improved following yoga (0.59 ± 0.5 to 0.18 ± 0.4, p = 0.039). There was a significant reduction in the cSP from baseline (138.07 ± 27.5 ms) to 4 weeks of yoga therapy (116.94 ± 18.2 ms, p = 0.004). In addition, a significant reduction in SICI was observed after four weeks of yoga therapy (0.22 ± 0.10) to (0.46 ± 0.23), p = 0.004).Conclusion: Yoga intervention can significantly improve postural stability in patients with PD. A significant reduction of cSP and SICI suggests a reduction in GABAergic neurotransmission following yoga therapy that may underlie the improvement observed in postural stability.Clinicaltrialsgov identifier: CTRI/2019/02/017564.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"102-109"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Real-World Study of Nusinersen Effects in Adults with Spinal Muscular Atrophy Type 2 and 3. 对患有脊髓性肌肉萎缩症 2 型和 3 型的成人进行的一项有关 Nusinersen 效果的真实世界研究。

IF 2.9 4区医学

Canadian Journal of Neurological Sciences Pub Date : 2025-01-01 Epub Date: 2024-03-27 DOI: 10.1017/cjn.2024.49

Isabelle Côté, Victoria Hodgkinson, Marianne Nury, Louis Bastenier-Boutin, Xavier Rodrigue

{"title":"A Real-World Study of Nusinersen Effects in Adults with Spinal Muscular Atrophy Type 2 and 3.","authors":"Isabelle Côté, Victoria Hodgkinson, Marianne Nury, Louis Bastenier-Boutin, Xavier Rodrigue","doi":"10.1017/cjn.2024.49","DOIUrl":"10.1017/cjn.2024.49","url":null,"abstract":"Background: Spinal muscular atrophy (SMA) is a progressive genetic disorder characterized by muscle weakness ultimately leading to pulmonary impairments that can be fatal. The recent approval of nusinersen, a disease-modifying therapy, substantially changed the prognosis for patients, particularly in children. However, real-world evidence about its long-term effectiveness in adults remains limited. This study aimed to document longitudinal data on motor function, pulmonary function and patient-reported outcome measures of Canadian adults with SMA type 2 and 3 treated with nusinersen.Methods: Outcomes from 17 patients were collected at the Institut de réadaptation en déficience physique de Québec during routine clinical visits over 36 months post nusinersen treatment, using the Hammersmith Functional Motor Scale Expanded for SMA (HFMSE), Revised Upper Limb Module (RULM), 6-Minute Walk Test (6MWT), Children's Hospital of Philadelphia Adult Test of Neuromuscular Disorders (CHOP-ATEND), SMA functional rating scale (SMAFRS), pulmonary function testing and subjective changes reported by patients.Results: After 36 months, 9 patients showed motor function improvement. Changes beyond the minimal clinically important difference were seen for four patients on the HFMSE, four patients on the RULM and five patients on the 6MWT. Pulmonary function remained stable for most subjects. Subjective positive changes were reported in 88% of patients and five patients showed improvement in the SMAFRS.Conclusion: This real-world study demonstrates the positive effects of nusinersen in adults with SMA types 2 and 3. Although stabilizing the patient's condition is considered therapeutic success, this study shows an improvement in motor function and subjective gains in several patients.","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"119-128"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140295383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0